PC
TRIL

Polar Capital’s Trillium Therapeutics Inc. TRIL Stock Holding History

Polar Capital’s Portfolio TRIL Stock Details TRIL Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2016
Q4 		– Sell
-33,000
Closed -$488K – 275
2016
Q3 		$488K Buy
+33,000
New +$380K 0.01% 243

Other funds holding TRIL

JHIU
Janus Henderson Investors US Denver, Colorado $122B AUM 18.26% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Franklin Resources
Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return
ACA
Avoro Capital Advisors New York $10.2B AUM 149.19% 1-Year Est. Return
IBT
International Biotechnology Trust London, United Kingdom $297M AUM 17.25% 1-Year Est. Return
CS
Candriam SCA Strassen, Luxembourg, Luxembourg $19.3B AUM 39.18% 1-Year Est. Return
OM
Opaleye Management Boston, Massachusetts $759M AUM 124.8% 1-Year Est. Return
SAM
Sectoral Asset Management Montreal, Quebec, Canada $121M AUM 73.47% 1-Year Est. Return
NLVP
New Leaf Venture Partners New York $43M AUM 25.55% 1-Year Est. Return
PI
Putnam Investments Boston, Massachusetts $75.7B AUM 34.45% 1-Year Est. Return

Polar Capital's TRIL Position: Q4 2016 in Review

Polar Capital sold out of Trillium Therapeutics Inc. (TRIL) in Q4 2016, closing a stake of 33,000 shares — an estimated $488K sold.

Polar Capital first reported a position in TRIL in Q3 2016 and held it in 1 quarter. The position peaked at $488K in Q3 2016. 29 funds tracked by Wall St. Rank hold TRIL as of Q4 2016.

  • Polar Capital reported no remaining Trillium Therapeutics Inc. position as of Q4 2016 after selling out during the quarter.
  • Polar Capital sold 33,000 Trillium Therapeutics Inc. shares in Q4 2016, an estimated $488K.
  • Polar Capital first reported a position in Trillium Therapeutics Inc. in Q3 2016 and held it in 1 quarter.
  • Polar Capital's Trillium Therapeutics Inc. position peaked at $488K in Q3 2016.
  • 29 funds tracked by Wall St. Rank held Trillium Therapeutics Inc. as of Q4 2016.

Based on Polar Capital's 13F filing for Q4 2016, filed 14 Feb 2017.